PuraPharm (HKSE:01498) PEG Ratio: N/A (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01498 PuraPharm Corporation Ltd HKSE:01498
23 GF Score
Price HK$0.28
GF Value HK$0.51
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PuraPharm PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, PuraPharm's PE Ratio without NRI is 0.00. PuraPharm's 5-Year EBITDA growth rate is 0.00%. Therefore, PuraPharm's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for PuraPharm's PEG Ratio or its related term are showing as below:



HKSE:01498's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.81
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


PuraPharm  (HKSE:01498) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


PuraPharm PEG Ratio Related Terms


PuraPharm PEG Ratio Historical Data

* Premium members only.

The historical data trend for PuraPharm's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PuraPharm PEG Ratio Chart

PuraPharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PuraPharm Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:01498 vs ZTS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's PEG Ratio distribution charts can be found below:

* The bar in red indicates where PuraPharm's PEG Ratio falls into.


HKSE:01498
23GF Score
PuraPharm Corporation Ltd HKSE:01498
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PuraPharm PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

PuraPharm's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is PuraPharm (HKSE:01498) Overvalued in 2026?

Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued. The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51. GuruFocus considers PuraPharm to be Possible Value Trap.

Key valuation signals for HKSE:01498:

  • PEG Ratio: N/A
  • GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PuraPharm Business Description

Address Phase One, Unit 201-207, 2nd Floor, Wireless Centre, Hong Kong Science Park, New Territories, Pak Shek Kok, Tai Po, Hong Kong, HKG
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score

Get the complete analysis for HKSE:01498

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.28
Price
HK$0.51
GF Value